Association of Plasma High-Density Lipoprotein Cholesterol Level With Risk of Fractures in Healthy Older Adults.

Importance Increased levels of high-density lipoprotein cholesterol (HDL-C) have been associated with osteoporosis. Preclinical studies have reported that HDL-C reduces bone mineral density by reducing osteoblast number and function. However, the clinical significance of these findings is unclear. Objective To determine whether higher HDL-C levels are predictive of an increased fracture risk in healthy older adults. Design, Setting, and Participants This cohort study is a post hoc analysis of data from the Aspirin in Reducing Events in the Elderly (ASPREE) clinical trial and the ASPREE-Fracture substudy. ASPREE was a double-blind, randomized, placebo-controlled primary prevention trial of aspirin that recruited participants between 2010 and 2014. These comprised community-based older adults (16 703 Australians aged ≥70 years, 2411 US participants ≥65 years) without evident cardiovascular disease, dementia, physical disability, and life-limiting chronic illness. The ASPREE-Fracture substudy collected data on fractures reported postrandomization from Australian participants. Cox regression was used to calculate hazard ratio (HR) and 95% CI. Data analysis for this study was performed from April to August 2022. Exposure Plasma HDL-C. Main Outcomes and Measures Fractures included were confirmed by medical imaging and included both traumatic and minimal trauma fractures. Fractures were adjudicated by an expert review panel. Results Of the 16 262 participants who had a plasma HDL-C measurement at baseline (8945 female participants [55%] and 7319 male [45%]), 1659 experienced at least 1 fracture over a median (IQR) of 4.0 years (0.02-7.0 years). In a fully adjusted model, each 1-SD increment in HDL-C level was associated with a 14% higher risk of fractures (HR, 1.14; 95% CI, 1.08-1.20). The results remained similar when these analyses were stratified by sex. Sensitivity and stratified analyses demonstrated that these associations persisted when the analyses were repeated to include only (1) minimal trauma fractures, (2) participants not taking osteoporosis medications, (3) participants who were never smokers and reported that they did not drink alcohol, and (4) participants who walked outside for less than 30 minutes per day and reported no participation in moderate/vigorous physical activity and to examine only (5) statin use. No association was observed between non-HDL-C levels and fractures. Conclusions and Relevance This study suggests that higher levels of HDL-C are associated with an increased fracture risk. This association was independent of common risk factors for fractures.

[1]  L. Kuller,et al.  The Association of Lipids and Lipoproteins with Hip Fracture Risk the Cardiovascular Health Study. , 2022, The American journal of medicine.

[2]  Yan V. Sun,et al.  Association Between High-Density Lipoprotein Cholesterol Levels and Adverse Cardiovascular Outcomes in High-risk Populations. , 2022, JAMA cardiology.

[3]  Yong Li,et al.  Blood lipid levels in patients with osteopenia and osteoporosis:a systematic review and meta-analysis , 2020, Journal of Bone and Mineral Metabolism.

[4]  Andrea Bonnin Márquez,et al.  High-Density Lipoprotein Modifications: A Pathological Consequence or Cause of Disease Progression? , 2020, Biomedicines.

[5]  H. Deng,et al.  Detecting causal relationship between metabolic traits and osteoporosis using multivariable Mendelian randomization , 2020, Osteoporosis International.

[6]  J. Eisman,et al.  Establishing baseline absolute risk of subsequent fracture among adults presenting to hospital with a minimal-trauma-fracture , 2020, BMC Musculoskeletal Disorders.

[7]  P. Zeng,et al.  Are blood lipids risk factors for fracture? Integrative evidence from instrumental variable causal inference and mediation analysis using genetic data. , 2019, Bone.

[8]  M. Giladi,et al.  Reduced Activity of Geranylgeranyl Diphosphate Synthase Mutant Is Involved in Bisphosphonate-Induced Atypical Fractures , 2018, Molecular Pharmacology.

[9]  Suzanne G. Orchard,et al.  Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study , 2017, The journals of gerontology. Series A, Biological sciences and medical sciences.

[10]  F. Chen,et al.  Effects of Anacetrapib in Patients With Atherosclerotic Vascular Disease , 2018 .

[11]  B. Nordestgaard,et al.  Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies , 2017, European heart journal.

[12]  C. Granger,et al.  Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease , 2017, The New England journal of medicine.

[13]  H. Blair,et al.  High-density lipoprotein (HDL) metabolism and bone mass. , 2017, The Journal of endocrinology.

[14]  W. Johnson,et al.  Triglyceride Levels and Fracture Risk in Midlife Women: Study of Women's Health Across the Nation (SWAN). , 2016, The Journal of clinical endocrinology and metabolism.

[15]  D. Deligianni,et al.  Apolipoprotein A-1 regulates osteoblast and lipoblast precursor cells in mice , 2016, Laboratory Investigation.